A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

Completed · Phase 3 · Has a placebo group

Conditions studied: Hormone Receptor Positive Breast Cancer

In brief

The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast cancer who have not had prior hormonal treatment.

Key facts

Study ID

NCT01602380

Run by

AstraZeneca

People needed

462

Starts

2012-10-17

Expected to finish

2026-01-16

Last updated by the study team

2026-02-27

Who can join

Age: 18 and older, up to 130. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histological confirmation of breast cancer in post menopausal women (age >=60). Positive hormone receptor status (ER +ve and/or PgR +ve) of primary or metastatic tumour tissue based on local laboratory assessment.
• EITHER locally advanced disease (1 line of chemotherapy allowed only if remain unsuitable for therapy of curative intent) OR Metastatic disease. (1 line of chemotherapy for breast cancer allowed only if subsequent evidence of further progressive disease)
• At least 1 lesion (measurable and/or non-measurable) that can be accurately assessed at baseline and is suitable for repeated assessment.
• Postmenopausal women, fulfilling 1 of:
• Prior bilateral oophorectomy
• Age >60 years
• Age < 60 years and amenorrheic for 12+months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and FSH and oestradiol in the postmenopausal range

You may not qualify if…

• Presence of life-threatening metastatic disease
• Any of:
• Extensive hepatic involvement
• involving brain or meninges
• symptomatic pulmonary lymph spread
• Discrete lung metastases are acceptable if respiratory function is not significantly compromised
• Prior systemic therapy for breast cancer other than one line of cytotoxic chemotherapy (the last dose of chemotherapy must have been received more than 28 days prior to randomisation)
• Radiation therapy if not completed within 28 days prior to randomisation (with the exception of radiotherapy given for control of bone pain, started prior to randomisation). Prior hormonal treatment for breast cancer.
• Current or prior malignancy within previous 3 years (other than breast cancer or adequately treated basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix).

Where it is running

• Research Site — Savannah, Georgia, United States
• Research Site — Auburn, Maine, United States
• Research Site — Worcester, Massachusetts, United States
• Research Site — Detroit, Michigan, United States
• Research Site — St Louis, Missouri, United States
• Research Site — Lincoln, Nebraska, United States
• Research Site — Somerset, New Jersey, United States
• Research Site — Columbus, Ohio, United States
• Research Site — Montgomery, Ohio, United States
• Research Site — Memphis, Tennessee, United States
• Research Site — Salt Lake City, Utah, United States
• Research Site — La Rioja, Argentina
• Research Site — Mar del Plata, Argentina
• Research Site — Pergamino, Argentina
• Research Site — Rosario, Argentina
• Research Site — Porto Alegre, Brazil
• Research Site — Santo André, Brazil
• Research Site — Abbotsford British Columbia, British Columbia, Canada
• Research Site — Vancouver, British Columbia, Canada
• Research Site — Kitchener, Ontario, Canada
• Research Site — Thunder Bay, Ontario, Canada
• Research Site — Montreal, Quebec, Canada
• Research Site — Montreal, Quebec, Canada
• Research Site — Chengdu, China
• Research Site — Modesto, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.